ADRA2C; ADRA2A; ADRA2B; CHRM1; CHRM2; CHRM3; CHRM5; | |
BLM; GFER; HSD17B10; ALDH1A1; POLB; | |
CA12; CA9; CA7; | |
CASP1; CASP7; | |
HIF1A; NFKB1; | |
LMNA; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
Small molecule receptor (family A GPCR) | CHRM1 | Muscarinic acetylcholine receptor M1 | P11229 | CHEMBL216 |
Small molecule receptor (family A GPCR) | CHRM2 | Muscarinic acetylcholine receptor M2 | P08172 | CHEMBL211 |
Small molecule receptor (family A GPCR) | CHRM3 | Muscarinic acetylcholine receptor M3 | P20309 | CHEMBL245 |
Small molecule receptor (family A GPCR) | CHRM5 | Muscarinic acetylcholine receptor M5 | P08912 | CHEMBL2035 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0050896; response to stimulus | GO:0007197; adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway | 9.155E-12 | 6.645E-08 | CHRM1, CHRM2, CHRM3, CHRM5 |
MF | GO:0060089; molecular transducer activity | GO:0016907; G-protein coupled acetylcholine receptor activity | 9.155E-12 | 6.645E-08 | CHRM1, CHRM2, CHRM3, CHRM5 |
BP | GO:0050896; response to stimulus | GO:0007207; phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway | 2.744E-11 | 1.195E-07 | CHRM1, CHRM2, CHRM3, CHRM5 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.744E-11 | 1.195E-07 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 9.011E-10 | 2.453E-06 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 1.685E-09 | 4.017E-06 | ADRA2A, ADRA2B, ADRA2C |
BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 6.736E-09 | 9.167E-06 | ADRA2A, ADRA2B, ADRA2C |
BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 6.736E-09 | 9.167E-06 | ADRA2A, ADRA2B, ADRA2C |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.736E-09 | 9.167E-06 | CYP1A2, CYP2C9, CYP3A4 |
BP | GO:0023052; signaling | GO:0007271; synaptic transmission, cholinergic | 3.155E-08 | 2.929E-05 | CHRM1, CHRM2, CHRM3, CHRM5 |
BP | GO:0009987; cellular process | GO:0010700; negative regulation of norepinephrine secretion | 9.399E-08 | 6.822E-05 | ADRA2A, ADRA2B, ADRA2C |
MF | GO:0005488; binding | GO:0051379; epinephrine binding | 9.399E-08 | 6.822E-05 | ADRA2A, ADRA2B, ADRA2C |
BP | Unclassified; | GO:0003056; regulation of vascular smooth muscle contraction | 1.409E-07 | 9.296E-05 | ADRA2B, CHRM1, CHRM3 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.639E-07 | 1.642E-04 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.681E-07 | 2.164E-04 | CYP1A2, CYP2C9, CYP3A4 |
CC | GO:0044456; synapse part | GO:0043679; axon terminus | 5.991E-07 | 2.965E-04 | ADRA2C, CHRM1, CHRM2, CHRM3 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 7.593E-07 | 3.674E-04 | CA12, CA7, CA9 |
BP | GO:0009987; cellular process | GO:0071880; adenylate cyclase-activating adrenergic receptor signaling pathway | 1.895E-06 | 7.641E-04 | ADRA2A, ADRA2B, ADRA2C |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.936E-06 | 1.084E-03 | CYP1A2, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 4.435E-06 | 1.558E-03 | CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004435; phosphatidylinositol phospholipase C activity | 4.834E-06 | 1.645E-03 | CHRM1, CHRM3, CHRM5 |
BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 9.833E-06 | 2.974E-03 | ADRA2A, ADRA2B, ADRA2C |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 9.833E-06 | 2.974E-03 | CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.116E-05 | 3.285E-03 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.171E-05 | 3.401E-03 | CA12, CA7, CA9 |
BP | GO:0032501; multicellular organismal process | GO:0046541; saliva secretion | 1.476E-05 | 4.175E-03 | CHRM1, CHRM3 |
MF | GO:0005488; binding | GO:0020037; heme binding | 1.764E-05 | 4.862E-03 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.159E-05 | 5.636E-03 | CA12, CA7, CA9 |
CC | GO:0045202; synapse | GO:0032279; asymmetric synapse | 4.124E-05 | 9.977E-03 | CHRM2, CHRM3 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2C; ADRA2B |
C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | CHRM1; CHRM3 |
N00-N99: Diseases of the genitourinary system | Overactive bladder | N32.81 | CHRM3 |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | CHRM5 |
A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | CHRM1; CHRM1; CHRM5 |
K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C; CHRM1; CHRM2 |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | CHRM1; CHRM1; CHRM2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | CHRM5 |
J00-J99: Diseases of the respiratory system | Asthma | J45 | ADRA2C; CHRM2 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Visceral spasms | R25.2 | CHRM1 |
C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
G00-G99: Diseases of the nervous system G00-G99 | Brain diseases | G00-G99 | CHRM5 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | CHRM2 |
NA: NA | Abdominal stomach pain | NA | CHRM1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1 |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | CHRM3 |
C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRA2C |
NA: NA | Addiction | NA | CHRM2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Seborrhea | L21 | CHRM3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | CHRM1; CHRM1; CHRM1; CHRM5 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | CHRM1; CHRM5 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1 |
NA: NA | Schizoaffective disorders | NA | CHRM1 |
C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; CA9; NFKB1 |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
NA: NA | Functional bowel syndrome | NA | CHRM1 |
NA: NA | Spasms | NA | CHRM3 |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | CHRM2 |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; CHRM1; CHRM5 |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADRA2B; CHRM1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Sjogren's syndrome | M35.0 | CHRM3 |
G00-G99: Diseases of the nervous system G00-G99 | Central and peripheral nervous diseases | G96.9 | CHRM5 |
I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; CA9 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | CHRM1; CHRM3; CHRM5 |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADRA2C; ADRA2A; CHRM3 |
K00-K95: Diseases of the digestive system | Colitis | K50-K52 | CHRM5 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C |
N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | CHRM1; CHRM2; CHRM3; CHRM5 |
NA: NA | Dystonia | NA | CHRM1 |
NA: NA | Extrapyramidal disorders secondary to neuroleptic drug therapy | NA | CHRM1 |
NA: NA | Excessive sweating | NA | CHRM1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | CHRM1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C |
G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADRA2C; CHRM2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Stabilize muscle contractions | M00-M99 | CHRM2 |
K00-K95: Diseases of the digestive system | Stomach ulcer | K25-K27 | CHRM1; CHRM5 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Postoperative nausea and vomiting | R11 | CHRM3 |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADRA2C; CHRM1; CHRM3 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | CHRM1 |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnosing bronchial hyperreactivity | W88 | CHRM3 |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C; CHRM5 |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ADRA2C; CHRM1; CHRM2; CHRM3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Amnesia | F04 | CHRM5 |
H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C |
J00-J99: Diseases of the respiratory system | Obstructive lung diseases | J40-J44, J47 | CHRM3 |